Immunicum AB (publ) announced that the European Patent Office (EPO) has announced its intention to grant a patent pertaining to the production method of the company's therapeutic cancer vaccines. Immunicum's vaccine cells are comprised of white blood cells from healthy blood donors, so-called allogeneic dendritic cells, which via a unique refinement process are developed into highly immunogenic cells. The Company's unique vaccine concept is based on over 30 years of research in the field of transplantation immunology and uses a new method to activate the body's own immune system to attack tumor cells.